This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gururaj, A. E. Articles by Kumar, R. Search for Related Content PubMed PubMed Citation Articles by Gururaj, A. E. Articles by Kumar, R.

Novel Mechanisms of Resistance to Endocrine Therapy: Genomic and Nongenomic Considerations

Authors' Affiliations: ¹ Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas and ² Department of Genetics and Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana

Requests for reprints: Rakesh Kumar, Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-745-3558; Fax: 713-745-3792; E-mail: rkumar{at}mdanderson.org.

Selective estrogen receptor (ER) modulators have been the most commonly used neoadjuvant therapy for hormone-dependent breast cancer. However, resistance to endocrine therapy, either inherent or acquired during treatment, presents a major challenge in disease management. The causes of resistance to hormone therapy are not well understood and are the subject of active investigation. It is increasingly clear that decreasing sensitivity of ER-positive breast cancer cells to antiestrogens is caused by several factors. Cross talk between ER and growth factor signaling has emerged as a critical factor in endocrine resistance. Here, we present evidence that receptor tyrosine kinase signaling also plays a role in resistance by controlling the subcellular localization of ER signaling components. Localization of ER in either the nuclear or cytoplasmic compartments has functional implications. Recent work suggests that dynein light chain 1, a recently identified substrate of p21-activated kinase 1, modulates ER transactivation functions through a novel ER coactivator function. Likewise, receptor tyrosine kinase signaling can also alter the expression of ER coregulators such as metastasis-associated antigen 1, leading to hormonal independence. Furthermore, proline-, glutamic acid-, leucine-rich protein 1, an ER coactivator involved in both genomic and nongenomic signaling pathways, is activated by epidermal growth factor receptor and plays a prominent role in resistance to tamoxifen. These recent advances suggest new targeted therapeutic approaches that may lead to either reversion or prevention of endocrine resistance in breast tumors.

This article has been cited by other articles:

				P. Bhat-Nakshatri, G. Wang, N. R. Collins, M. J. Thomson, T. R. Geistlinger, J. S. Carroll, M. Brown, S. Hammond, E. F. Srour, Y. Liu, et al. Estradiol-regulated microRNAs control estradiol response in breast cancer cells Nucleic Acids Res., June 14, 2009; (2009) gkp500v1. [Abstract] [Full Text] [PDF]

				M. Lombardi, G. Castoria, A. Migliaccio, M. V. Barone, R. Di Stasio, A. Ciociola, D. Bottero, H. Yamaguchi, E. Appella, and F. Auricchio Hormone-dependent nuclear export of estradiol receptor and DNA synthesis in breast cancer cells J. Cell Biol., July 28, 2008; 182(2): 327 - 340. [Abstract] [Full Text] [PDF]

				J W Assender, J M W Gee, I Lewis, I O Ellis, J F R Robertson, and R I Nicholson Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer J. Clin. Pathol., November 1, 2007; 60(11): 1216 - 1221. [Abstract] [Full Text] [PDF]

				S. L. Young Complexity in Endometrial Estradiol Signaling Reproductive Sciences, October 1, 2007; 14(7): 627 - 628. [PDF]

				B. Shi, J. Liang, X. Yang, Y. Wang, Y. Zhao, H. Wu, L. Sun, Y. Zhang, Y. Chen, R. Li, et al. Integration of Estrogen and Wnt Signaling Circuits by the Polycomb Group Protein EZH2 in Breast Cancer Cells Mol. Cell. Biol., July 15, 2007; 27(14): 5105 - 5119. [Abstract] [Full Text] [PDF]

				M. V. Karamouzis, J. R. Grandis, and A. Argiris Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas JAMA, July 4, 2007; 298(1): 70 - 82. [Abstract] [Full Text] [PDF]

				K. Narita, J. Chien, S. A. Mullany, J. Staub, X. Qian, W. L. Lingle, and V. Shridhar Loss of HSulf-1 Expression Enhances Autocrine Signaling Mediated by Amphiregulin in Breast Cancer J. Biol. Chem., May 11, 2007; 282(19): 14413 - 14420. [Abstract] [Full Text] [PDF]

				M. Karamouzis, P. Konstantinopoulos, and A. Papavassiliou Intriguing issues of EGFR targeting in head and neck cancer Ann. Onc., May 1, 2007; 18(5): 962 - 962. [Full Text] [PDF]

				D. W. Good Nongenomic Actions of Aldosterone on the Renal Tubule Hypertension, April 1, 2007; 49(4): 728 - 739. [Full Text] [PDF]

				M. Brama, S. Basciani, S. Cherubini, S. Mariani, S. Migliaccio, M. Arizzi, G. Rosano, G. Spera, and L. Gnessi Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment Endocr. Relat. Cancer, March 1, 2007; 14(1): 61 - 72. [Abstract] [Full Text] [PDF]

				E Tiligada Chemotherapy: induction of stress responses Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S115 - S124. [Abstract] [Full Text] [PDF]